Qiagen (NYSE:QGEN – Get Rating) and Outlook Therapeutics (NASDAQ:OTLK – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares Qiagen and Outlook Therapeutics' net margins, return on equity and return on assets.
Get
Qiagen alerts:
| Net Margins | Return on Equity | Return on Assets |
| Qiagen | 22.75% | 19.26% | 9.92% |
| Outlook Therapeutics | N/A | -237.91% | -125.36% |
Analyst Recommendations
This is a summary of recent recommendations for Qiagen and Outlook Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Qiagen | 0 | 4 | 1 | 0 | 2.20 |
| Outlook Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Qiagen currently has a consensus price target of $54.50, indicating a potential upside of 29.24%. Outlook Therapeutics has a consensus price target of $6.50, indicating a potential upside of 450.85%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Qiagen.
Volatility and Risk
Qiagen has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Valuation and Earnings
This table compares Qiagen and Outlook Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Qiagen | $2.25 billion | 4.25 | $512.60 million | $2.22 | 19.00 |
| Outlook Therapeutics | N/A | N/A | -$53.16 million | ($0.33) | -3.58 |
Qiagen has higher revenue and earnings than Outlook Therapeutics. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
55.7% of Qiagen shares are owned by institutional investors. Comparatively, 11.7% of Outlook Therapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 2.3% of Outlook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Qiagen beats Outlook Therapeutics on 9 of the 13 factors compared between the two stocks.
About Qiagen
(Get Rating)
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
About Outlook Therapeutics
(Get Rating)
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
